about
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesActivation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysisPrognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysisPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyRelevance of randomised controlled trials in oncology.In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.Drug resistance in metastatic castration-resistant prostate cancer.Achilles' heel of triple negative cancerTherapeutic potential of ERK5 targeting in triple negative breast cancerExtended adjuvant tamoxifen for early breast cancer: a meta-analysis.Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumorsTrastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancerConcomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.New options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy.Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.Neuregulins and cancer.Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.Personalized therapies in the cancer "omics" eraPreclinical development of molecular-targeted agents for cancer.Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.The evolving landscape of protein kinases in breast cancer: clinical implications.Management of small HER2 overexpressing tumours.Targeting HER receptors in cancer.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?Fulvestrant for advanced breast cancer: a meta-analysis.Phase III trials of targeted anticancer therapies: redesigning the concept.Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.
P50
Q26786243-0405F3B0-F6A4-42E6-B082-7FBA29A47626Q26830671-1A76133E-F265-4AE4-BEB0-DF1461E6A21CQ27001079-3AA68159-F12F-4242-B5AB-7834C05ED349Q27022482-FB8CDCA3-8838-4934-9BF7-AF9501F3FBF7Q28545130-A5D8149D-A7EC-4134-9874-26AA85D2AD57Q30240233-F448041C-33DA-4BD4-AFC2-8B0F23D75DF2Q31105168-A55529D9-88CC-4A68-8331-A7CCA486840DQ33591876-9A830D66-3BFD-4CF1-B33C-7E4ED7ACE4E0Q33612132-91CBF320-E94A-407C-8B52-F2B78338A0F5Q34139362-86E5A68D-31F5-45E1-B68E-0059868FBD87Q34781145-075692A9-449E-455E-AF85-5E0156E08B5FQ34956816-1BD4241A-4C62-4AAE-B361-75FBAAE69307Q35106041-366EC72A-C14F-4693-B390-E77B19EF2BF0Q35687851-98EFB07F-D272-4744-A7D0-010D6CBC0A12Q36009795-CAFBB7D1-0A29-4E15-9AEF-573B9A19B4AAQ36363060-69D8E527-8351-43B8-BFDC-B72F137F557CQ36389175-97E0BEA9-3F0C-4A6B-82D0-D1089489150EQ36413944-66316AEB-EA15-4E71-8B59-CE60A3711090Q36440599-7A988A2E-3C98-4D58-8201-C3DB0A54F7A2Q36490409-14A5804B-CFCE-428A-9859-A33652A02DC7Q36544553-B3EDE21C-BCA4-4877-802C-363123B789FAQ36544999-6FED95B1-9294-427D-936E-9D9F1B52F586Q36557500-427F65EB-E170-4E3E-A562-731A7BA047C2Q37056884-C47ECEDD-1EA3-4B0F-A5A9-56B6F77CD74CQ37087079-57EC2A0A-0492-4F69-89B1-8F746A2533D6Q37179990-385D7C25-79E2-4823-AD85-1E24892FAC3EQ37564335-05AC1E0C-2E1D-4B7A-9767-3E9018B4ED5AQ37592627-64A03963-2FB1-4692-8632-76E03989F39DQ37681170-7F3FCA86-DCE3-4DE9-8621-DB5A540C27E7Q37776547-D63E3A5A-A30A-4641-A713-E3CC30C06E3AQ37816960-EB4AF6AB-245F-4BEA-A10A-6ADAB062FD32Q37888979-1B64D000-49A4-45E3-B75D-B918DC613D4DQ37899689-0FB317E7-F87A-478A-9D1E-F37947BE6CE3Q38019094-0BBC31DD-C857-4686-B4D1-16AE3EB69595Q38041467-CC14C5DF-E58C-4CF9-981A-15AD642F26C8Q38042989-70BDDBF9-5C50-480B-B66D-5D533774BA07Q38055067-353EA805-C751-4208-B472-0F43F2FFFB4FQ38114241-9D34F98B-D675-4890-9C16-66DB241B9C7FQ38123784-021EB8DC-66B2-439A-A99C-4934C1029119Q38165914-DD48B28F-DDB5-4F30-B015-6B5EE6263DA5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alberto Ocana
@ast
Alberto Ocana
@en
Alberto Ocana
@es
Alberto Ocana
@nl
Alberto Ocana
@sl
type
label
Alberto Ocana
@ast
Alberto Ocana
@en
Alberto Ocana
@es
Alberto Ocana
@nl
Alberto Ocana
@sl
altLabel
Alberto Ocana
@en
prefLabel
Alberto Ocana
@ast
Alberto Ocana
@en
Alberto Ocana
@es
Alberto Ocana
@nl
Alberto Ocana
@sl
P106
P21
P31
P496
0000-0002-1067-9630